Eversense® Non-adjunctive Use Post Approval Study
A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 925 participants.
Also called NCT04836546
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose other
- Phase
- Not applicable
- Enrolled
- 925 participants
- Sponsor
- Registry
-
NCT04836546
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT04836546. Allocation not applicable; no masking; primary purpose other. Start 2021-04-13 (actual); primary completion 2026-03-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Eversense® Non-adjunctive Use Post Approval Study
- Acronym
- NA-PAS
- Condition
- Diabetes
- Intervention (Device)
- Blood glucose meter
- Intervention (Device)
- Eversense CGM System
- Lead sponsor
- Senseonics, Inc.
Record details
- Record id
cardio:ct-nct04836546- Content hash
3b59c8f6652276e3bb22c79aca8f282052dc7dfced0d1e2ac631a3a1320c3f78